

## Part I History and Epidemiology

<b>1 History of Multiple Myeloma.....</b>	<b>3</b>
Robert A. Kyle and David P. Steensma	
1.1 Ancient Origins .....	4
1.1.1 Early Well-Documented Cases.....	4
1.2 Henry Bence Jones (1813–1873) .....	7
1.3 Other Contributions to Bence Jones Proteinuria .....	10
1.4 Other Early Cases of Multiple Myeloma .....	11
1.4.1 The Case of Dr. Loos .....	11
1.4.2 The First Myeloma Case in America .....	12
1.4.3 Recognition of the Poor Prognosis Associated with Bence Jones Protein .....	13
1.4.4 Case Series .....	13
1.4.5 Plasma Cells .....	13
1.4.6 Antibodies .....	14
1.4.7 Electrophoresis .....	14
1.4.8 Monoclonal Versus Polyclonal Gammopathies .....	15
1.5 Alkylator and Corticosteroid-Based Therapy .....	15
1.5.1 Urethane .....	15
1.5.2 Melphalan.....	16
1.5.3 Prednisone .....	16
1.5.4 Alkylator Combinations .....	16
1.6 Stem Cell Transplantation .....	17
1.6.1 Novel Agents.....	17
References .....	19

<b>2 Epidemiology of Multiple Myeloma .....</b>	<b>25</b>
Nikolaus Becker	
2.1 Descriptive Epidemiology .....	26
2.2 Etiology .....	26
2.2.1 Tobacco .....	26
2.2.2 Alcohol .....	29
2.2.3 Diet .....	29
2.2.4 Obesity .....	29
2.2.5 Physical Activity .....	30
2.2.6 Hormonal Factors .....	30
2.2.7 Environment and Occupation .....	30
2.2.8 Ionizing Radiation .....	30
2.2.9 Inheritance .....	31
2.2.10 Medical History, Viruses, Immunological Conditions .....	31
2.3 Summary .....	31
 <b>Part II Pathophysiology</b>	
 <b>3 Molecular Pathogenesis of Multiple Myeloma:</b>	
<b>Chromosomal Aberrations, Changes in Gene Expression,</b>	
<b>Cytokine Networks, and the Bone Marrow Microenvironment .....</b>	<b>39</b>
Bernard Klein, Anja Seckinger, Thomas Moehler, and Dirk Hose	
3.1 Survival, Growth, and Inhibitory Factors of Normal Plasma Cells .....	40
3.1.1 Survival and Growth Factors of Normal Plasma Cells and Their Generation .....	40
3.1.2 Inhibitory Factors Expressed by Normal Plasma Cells .....	43
3.2 Chromosomal Aberrations .....	44
3.2.1 Background and Methods .....	44
3.2.2 Types of Chromosomal Aberrations .....	46
3.2.3 Association of Chromosomal Aberrations .....	47
3.2.4 Clonal, Subclonal, and Progression-Related Aberrations and Chromosomal Instability .....	47
3.2.5 Prognostic Relevance of Chromosomal Aberrations .....	48
3.3 Changes in Gene Expression in Multiple Myeloma .....	50
3.3.1 Gene Expression–Based Classifications in Myeloma .....	50
3.3.2 Gene Expression and Risk Stratification .....	51
3.4 Proliferation and Cell Cycle Regulation .....	52
3.4.1 “Potential to Proliferate” of Normal Plasma Cells .....	52
3.4.2 D-Type Cyclin Expression in Myeloma .....	53
3.4.3 Proliferation of Malignant Plasma Cells .....	53
3.5 Myeloma Cell Survival and Proliferation Factors .....	54

3.5.1	Interferon Alpha/Interleukin-6 Family and Activation of the JAK/STAT and MAP Kinase Pathways .....	55
3.5.2	Factors Activating the PI-3 and MAP Kinase Pathways: Insulin-Like Growth Factor 1, Heparin-Binding Growth Factors.....	56
3.5.3	Heparin-Binding Factors .....	58
3.5.4	Factors Activating NF-Kappa B: BAFF Family .....	59
3.5.5	Hierarchy of Myeloma Cell Growth Factors and Potential Clinical Applications.....	59
3.6	Multiple Myeloma Cells and the Microenvironment.....	60
3.6.1	Pathogenesis of Myeloma-Induced Bone Disease .....	61
3.6.2	Patterns and Healing of Bone Defects.....	63
3.6.3	Therapeutic Strategies for Treatment and Prevention of Myeloma Bone Disease.....	64
3.7	Pathogenetic Model of Multiple Myeloma .....	64
3.7.1	Disease Activity, Tumor Load, and Molecular Characteristics of Myeloma Cells .....	67
3.7.2	Multistep Transformation of Myeloma Cell Model.....	69
3.7.3	Transformation of Bone Marrow Microenvironment Model .....	70
<b>4</b>	<b>Angiogenesis and Vasculogenesis in Multiple Myeloma:</b>	
	<b>Role of Inflammatory Cells .....</b>	<b>87</b>
	Angelo Vacca and Domenico Ribatti	
4.1	Introduction .....	87
4.2	Angiogenesis and Antiangiogenesis in Multiple Myeloma .....	88
4.3	The Role of Inflammatory Cells in Tumor Angiogenesis .....	89
4.4	The Involvement of Macrophages in Vascular Mimicry in MM.....	90
4.5	The Involvement of Mast Cells in Vascular Mimicry in MM.....	91
4.6	Vasculogenesis by Hematopoietic Stem and Progenitor Cells.....	92
4.7	Concluding Remarks .....	93
<b>5</b>	<b>Immunology and Immunotherapeutic</b>	
	<b>Approaches in Multiple Myeloma .....</b>	<b>97</b>
	Christoph Schlude and Philipp Beckhove	
5.1	Introduction .....	97
5.2	Myeloma-Associated Antigens .....	98
5.3	Vaccination .....	99
5.4	Immune Evasion.....	101
5.5	Regulatory T Cells.....	102
5.6	Humoral Immunotherapy .....	102
5.7	Adoptive Cellular Therapy.....	103
5.8	Conclusion.....	104

## Part III Clinical Features

### 6 Monoclonal Gammopathy and Smoldering

#### **Multiple Myeloma: Diagnosis, Staging, Prognosis, Management** ..... 113

Jens Hillengass, Thomas Moehler, and Michael Hundemer

6.1	Definition of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (sMM).....	114
6.2	Prevalence of MGUS.....	114
6.3	Differential Diagnosis and Diagnostic Assessment .....	116
6.3.1	Initial Diagnostic Assessment .....	116
6.3.2	Follow-up Recommendations.....	117
6.4	Risk Factors for Progression .....	118
6.4.1	Prognostic Factors for Progression for Patients with MGUS.....	118
6.4.2	Prognostic Factors for Progression of sMM.....	119
6.4.3	Genetic Risk Stratification .....	122
6.5	Etiology and Pathogenesis of MGUS and sMM and Considerations Regarding Primary Prevention .....	122
6.5.1	Population-Based Studies.....	122
6.5.2	Concept of Chronic Antigenic Stimulation .....	122
6.5.3	Molecular Genetics and Cytogenetics.....	123
6.5.4	Concepts for Secondary Prevention of Progression to Multiple Myeloma and Other Lymphoproliferative Diseases.....	124
6.5.5	Summary of Clinical Studies to Halt Progression.....	124
6.6	Summary and Conclusions.....	126

### 7 Imaging in Multiple Myeloma ..... 133

Stefan Delorme and Andrea Baur-Melnyk

7.1	Introduction .....	133
7.2	Imaging Methods.....	134
7.2.1	Morphologic Imaging.....	134
7.2.2	Functional Imaging.....	135
7.3	Radiological–Pathological Correlation .....	136
7.4	Differential Diagnosis .....	142
7.5	Staging.....	143
7.6	Treatment Effects .....	144
7.7	Prognostic Factors .....	144
7.8	The Radiologist’s Tasks .....	145

## Part IV Therapy

### 8 Novel Drugs in Myeloma: Harnessing Tumour

#### **Biology to Treat Myeloma** ..... 151

Kevin Boyd, Faith E. Davies, and Gareth J. Morgan

8.1	Introduction .....	151
8.2	Intracellular Drug Targets.....	152

8.2.1	Targeting Signalling Pathways Within Myeloma Cells .....	152
8.2.2	Targeting the Unfolded Protein Response.....	158
8.2.3	Targeting Chromatin.....	159
8.2.4	Targeting Intracellular Cell Cycle Regulatory Proteins .....	162
8.3	Extracellular Drug Targets .....	163
8.3.1	Targeting Cytokines or Their Receptors.....	163
8.3.2	Targeting Myeloma Cell Adhesion Molecules.....	167
8.3.3	Targeting the Host Immune System .....	169
8.3.4	Targeting Bone Disease.....	171
8.4	Conclusion.....	173
<b>9</b>	<b>Firstline Treatment and Maintenance in Newly Diagnosed Multiple Myeloma Patients .....</b>	<b>189</b>
	Murielle Roussel, Thierry Facon, Philippe Moreau, Jean-Luc Harousseau, and Michel Attal	
9.1	Frontline Treatment in MM Patients Eligible for High-Dose Therapy .....	190
9.1.1	Induction Treatment: What Combination of New Drugs? .....	190
9.1.2	Autologous Stem Cell Transplantation Upfront or at the Time of Relapse?.....	194
9.1.3	Maintenance/Consolidation Treatment .....	195
9.2	Frontline Treatment in Elderly MM Patients .....	196
9.2.1	What Is the Best Combination with Alkylating Agents? .....	197
9.2.2	Firstline Treatment: Can New Agents Replace Alkylators? .....	200
9.2.3	Can We Reduce Toxicities of New Drugs-Incorporating Regimens? .....	201
9.2.4	Maintenance Therapy in Elderly .....	202
<b>10</b>	<b>High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma .....</b>	<b>207</b>
	Rainer Haas, Ingmar Bruns, Guido Kobbe, and Roland Fenk	
10.1	Introduction.....	208
10.2	Peripheral Blood Stem Cell Mobilization .....	208
10.2.1	The Role of Adhesion Molecules.....	208
10.2.2	The Role of Hematopoietic Growth Factors .....	210
10.2.3	The Role of Cytotoxic Stem Cell Mobilization.....	212
10.2.4	The Role of Pegfilgrastim for Stem Cell Mobilization .....	213
10.3	High-Dose Therapy and Autologous Stem Cell Transplantation.....	215
10.3.1	The Beginning of High-Dose Therapy in the 1980.....	215
10.3.2	The Role of Purging of the Autograft .....	216
10.3.3	The Role of the Conditioning Regimen .....	217
10.3.4	Supportive Care During High-Dose Chemotherapy .....	218
10.3.5	High-Dose Chemotherapy Is Superior to Conventional Chemotherapy.....	219
10.3.6	Timing of High-Dose Chemotherapy .....	221
10.3.7	Tandem Autologous Transplantation .....	221

10.3.8 The Role of Induction Treatment .....	222
10.3.9 The Role of Consolidation or Maintenance Treatment .....	223
10.3.10 Prognostic Factors .....	224
10.3.11 Targeted Versus High-Dose Chemotherapy .....	226
<b>11 Therapy of Relapsed and Refractory Multiple Myeloma .....</b>	<b>239</b>
Thomas Moehler and Hartmut Goldschmidt	
11.1 Introduction .....	240
11.2 Diagnostic Workup of Patients at Relapse .....	240
11.3 Conventional Treatment of Relapsed/Refractory Disease .....	240
11.4 High-Dose Chemotherapy (HDCT) Supported by Autologous Stem Cell Transplantation .....	241
11.5 Allogeneic Stem Cell Transplantation.....	242
11.6 Thalidomide and Immunomodulatory Drugs.....	245
11.6.1 Thalidomide as Single Agent and Combined with Corticosteroids .....	245
11.6.2 Thalidomide in Combination with Chemotherapy/Corticosteroids .....	246
11.6.3 Lenalidomide.....	249
11.6.4 Lenalidomide Combination Therapies.....	249
11.6.5 Pomalidomide.....	251
11.7 Bortezomib .....	251
11.7.1 Bortezomib Single Agent .....	251
11.7.2 Bortezomib Combination Therapy.....	252
11.8 Novel Proteasome Inhibitors.....	254
11.9 Combination of Novel Agents.....	255
11.10 Emerging Therapies and Novel Pathways.....	260
11.11 Prognostic Factors.....	260
11.12 Therapeutic Strategy for Relapsed/Refractory Myeloma Patients .....	260
<b>12 Allogeneic Transplantation in Multiple Myeloma .....</b>	<b>273</b>
Gösta Gahrton	
12.1 Introduction .....	274
12.2 Myeloablative High Dose Conditioning.....	274
12.3 Molecular Remission.....	275
12.4 Source of Stem Cells .....	275
12.5 Reduced Intensity conditioning (RIC) .....	276
12.5.1 Retrospective Studies .....	276
12.5.2 Prospective Studies.....	276
12.6 How to Improve Results of Allogeneic Transplantation? .....	279
12.6.1 Donor Lymphocyte Transfusions .....	279
12.6.2 NK Cells Have Antimyeloma Effect and Moderate GVHD .....	280
12.6.3 Role of Immunosuppressive Agents in the Conditioning Therapy .....	280
12.6.4 Targeted Drugs Pretransplant or Posttransplant .....	281
12.7 Conclusions .....	281

<b>13 Radiotherapy</b> .....	285
Sonja Krause, Jürgen Debus, and Dirk Neuhof	
13.1 Solitary Plasmocytoma.....	285
13.1.1 Diagnostic Workup.....	286
13.1.2 Radiotherapy of SBP.....	286
13.1.3 Radiotherapy of EP.....	287
13.1.4 Treatment Toxicity.....	287
13.2 Palliative Treatment of Multiple Myeloma.....	287
13.2.1 Pain Control.....	288
13.2.2 Recalcification.....	288
13.3 Total Body Irradiation (TBI).....	289
 <b>14 Osteoplastic Procedures for the Treatment of Vertebral Complications in Multiple Myeloma Patients</b> .....	293
Christian Kasperk and Ingo Grafe	
14.1 Introduction.....	294
14.2 Osteoplastic Procedures.....	294
14.3 Balloon Kyphoplasty.....	294
14.4 Vertebroplasty.....	295
14.5 Comparison of Kyphoplasty and Vertebroplasty.....	296
14.6 Indications and Contraindications.....	296
14.7 Randomized Controlled Studies of Osteoplastic Procedures for Vertebral Osteoporotic Fractures.....	297
14.8 Studies Using Kyphoplasty and Vertebroplasty in Patients with Multiple Myeloma.....	298
 <b>15 Supportive Therapy in Multiple Myeloma</b> .....	307
Heinz Ludwig and Niklas Zojer	
15.1 Introduction.....	307
15.2 Myeloma Bone Disease.....	308
15.2.1 Mechanisms of Bone Disease.....	308
15.2.2 Bone Fractures.....	309
15.2.3 Vertebral Lesions.....	309
15.2.4 Bisphosphonates.....	309
15.3 Hypercalcemia.....	314
15.3.1 Diagnosis and Symptoms.....	314
15.3.2 Treatment of Hypercalcemia.....	315
15.4 Anemia.....	316
15.4.1 Pathogenesis of Anemia.....	316
15.4.2 Clinical Symptoms of Anemia.....	316
15.4.3 Treatment of Anemia.....	317
15.5 Infections.....	320

---

15.5.1 Causes of Infections .....	320
15.5.2 Prophylaxis of Infections.....	321
15.5.3 Vaccination .....	322
15.5.4 Treatment of Infections .....	322
15.6 Pain.....	323
15.6.1 Characteristics and Causes of Pain.....	323
15.6.2 Medical Pain Treatment .....	324
15.7 Renal Failure .....	325
15.7.1 Prevalence and Causes of Renal Failure .....	325
15.7.2 Management of Myeloma-Induced Renal Failure.....	326
<b>Appendix.....</b>	<b>335</b>





<http://www.springer.com/978-3-540-85771-6>

Multiple Myeloma

Moehler, Th.; Goldschmidt, H. (Eds.)

2011, XXIV, 340 p., Hardcover

ISBN: 978-3-540-85771-6